

Dominion Way
Worthing, West Sussex
BN14 8SA, United Kingdom

T: +44 (0)1903 844 700
www.allergytherapeutics.com

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to what action you should take, you are recommended to seek your own financial advice from your stockbroker or other independent adviser authorised under the Financial Services and Markets Act 2000.

If you have sold or transferred all of your shares in Allergy Therapeutics plc, please forward this document, together with the accompanying documents, as soon as possible either to the purchaser or transferee or to the person who arranged the sale or transfer so they can pass these documents to the person who now holds the shares.

12 December 2025

Dear Shareholder,

Allergy Therapeutics plc

(Incorporated and registered in England and Wales under the Companies Act 2006 with registered no. 05141592)

Authority for allotment of up to 610,000,000 New Shares and disapplication of pre-emption rights to facilitate a Potential Equity Raise

Notice of General Meeting to be held on 29 December 2025

Thank you for registering to receive shareholder communications via our website.

The Board is considering potentially undertaking an equity raise which would be structured by issuing New Shares to new investors and/or existing shareholders in the Company for cash consideration in one or more private placements on a non-pre-emptive basis (the “**Potential Equity Raise**”).

In order to facilitate the Potential Equity Raise and to ensure that it could be swiftly concluded if it progresses, the Board is seeking specific shareholder approval at a General Meeting for the allotment and issue of up to 610,000,000 New Shares (which is approximately 10% of the Company's current issued share capital) in connection with the Potential Equity Raise, on terms that the Board may determine.

Please note that the Notice of General Meeting has been published on our website at www.allergytherapeutics.com. This letter is not a summary of the proposals to be put to the General Meeting in connection with the Potential Equity Raise and should not be regarded as a substitute for reading the whole document.

To access the document you will need to have Adobe Acrobat Reader which you can install free of charge via <https://get.adobe.com/uk/reader/>.

The General Meeting will be held at the offices of Cooley (UK) LLP, 22 Bishopsgate, London EC2N 4BQ, United Kingdom at 11:00 a.m. (UK time) on 29 December 2025.

Voting on the business of the General Meeting will be conducted by way of a poll, to reflect the voting instructions received. Our registrars, MUFG Corporate Markets, must receive your proxy appointment by 11:00 a.m. (UK time) on 23 December 2025. Registration of your proxy vote does not affect your right to attend and vote at the meeting in person, should you so wish.

Allergy Therapeutics plc
Registered in England and Wales
under company number 5141592

Registered Office: Dominion Way,
Worthing, West Sussex BN14 8SA

Shareholders can vote electronically via the Investor Centre, a free app for smartphone and tablet provided by MUFG Corporate Markets (the company's registrar). It allows you to securely manage and monitor your shareholdings in real time, take part in online voting, keep your details up to date, access a range of information including payment history and much more. The app is available to download on both the Apple App Store and Google Play, or by scanning the relevant QR code below. Alternatively, you may access the Investor Centre via a web browser at: <https://uk.investorcentre.mpms.mufg.com/>.



Download on the
App Store



GET IT ON
Google Play

Alternatively, you can contact the registrar MUFG Corporate Markets whose details are shown below and request a paper proxy. Shareholders who are CREST members may submit their CREST Proxy Instructions online via the CREST electronic appointment service.

Online voting is a more efficient, secure method of registering your vote, and is in line with the Company's intention to reduce its impact on the environment. If you need any help with registering your proxy vote online, please contact the Company's registrar, MUFG Corporate Markets, by calling them on 0371 664 0300 or, if calling from overseas, on +44 (0) 371 664 0300. Calls are charged at the standard geographic rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. We are open between 09:00 – 17:30, Monday to Friday excluding public holidays in England and Wales. You can also contact the registrar by email at shareholderenquiries@cm.mpms.mufg.com.

If you would like us to send you a hard copy of the Notice of General Meeting, please contact the registrar, MUFG Corporate Markets, using the contact details provided above.

Yours faithfully,

Karley Cheesman
Company Secretary

This communication has been sent to certain beneficial owners of shares who have been nominated by the registered holders of their shares to enjoy information rights in accordance with section 146 of the Companies Act 2006. Such persons are advised that, to vote, they must issue an instruction to the registered holder of their shares.